Poll: What Is the Best Way to Improve Biosimilar Access?

Article

Opinions are diverse on how best to clear the obstructions to biosimilar market entry and patient access.

Which of the following would best alleviate bottlenecks in biosimilar access?

A broader selection of biosimilars for each drug category
Improved physician training on biosimilar equivalence
Step therapy policies that promote the use of economical therapies
Mandatory biologics pricing disclosures by health plans
Related Videos
Brian Biehn
Chelsee Jensen, PharmD, BCPS
GBW 2023 webinar
Ryan Haumschild, PharmD, MS, MBA
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD
Stephen Hanauer, MD
Fran Gregory, PharmD, MBA
Related Content
© 2023 MJH Life Sciences

All rights reserved.